alexa Stem Cell Therapy For Amyotrophic Lateral Sclerosis Follow-up For 84 Patients
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Cell Science & Stem Cell Research
June 24-26, 2014 Valencia Conference Centre, Valencia, Spain

Francisco Ruiz-Navarro
ScientificTracks Abstracts: J Cell Sci Ther
DOI: 10.4172/2157-7013.S1.028
Abstract
A myotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal disease characterized by a progressive degeneration of lower and upper motor-neurons. Survival ranges reported are less than 3 years and the population-based study for long survival estimates a cumulative time-dependent survival at 1, 5 and 10 years from diagnosis with 76.2%, 23.4% and 11.8%. Today there is not treatment that change or intensively slow the futile end of ALS. There are several scientific evidence that stem cells produce a beneficial effect in neurodegeneration of ALS in animal models, there are also some ongoing clinical trials, with positive results in Phase I and II. Several trials around the world are now ongoing to elucidate which cell type is better and the characteristics of the population that will benefit more from these treatments. We analyzed 84 patients going under autologous mesenquimal stem cell transplantation with a point-of-care fashion and follow them for outcome. Survival modeling was performed using Kaplan-Meier analysis. Results : Taking time 0 as the moment of the transplantation the patients have 44% of survival at 11 months. When we take point 0 as the time of diagnosis the survival at 12, 24, 36 and 60 months was 89.2%, 81.4%, 64.5% and 58.7% since the diagnosis. Comparing to previous reports patients treated have 13% increased survival in the first year (survival of 89.2%) and a 35.3% increased in a 5-year period (survival of 58.7%). This study set sufficient information to future research in clinical trials
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords